Effect of anti-fibrotic therapy on regression of myocardial fibrosis after TAVI: 'As-treated' analysis of the Reduce-MFA DZHK 25-trial

29 August 2026 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy in valvular heart disease: atrial fibrillation and mitral regurgitation Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology